Live price temporarily unavailable.
Century Therapeutics (IPSC) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | $5.20M | $2.23M | $6.59M | $109.2M |
| Growth (year over year) | — | — | — | −57.0% | +194.8% | +1556.8% |
| Operating income | −$53.9M | −$94.9M | −$133.8M | −$146.5M | −$138.1M | −$17.3M |
| Operating margin | — | — | −2574.2% | −6556.9% | −2096.5% | −15.8% |
| Net income | −$53.6M | −$95.8M | −$130.9M | −$136.7M | −$126.6M | −$9.58M |
| Net margin | — | — | −2518.4% | −6115.1% | −1920.9% | −8.8% |
| EPS (diluted) | −$7.16 | −$2.96 | −$2.96 | −$2.30 | −$1.61 | −$0.14 |
| Balance sheet | ||||||
| Cash and equivalents | $27.2M | $56.4M | $84.3M | $47.3M | $58.4M | $61.9M |
| Total assets | $106.8M | $437.4M | $486.5M | $360.7M | $353.2M | $223.7M |
| Total liabilities | $33.4M | $41.1M | $183.8M | $175.9M | $191.9M | $64.8M |
| Long-term debt | $9.64M | $8.90M | $3.74M | — | — | — |
| Shareholders' equity | −$106.4M | $396.2M | $302.7M | $184.8M | $161.4M | $158.9M |
| Cash flow | ||||||
| Operating cash flow | −$41.3M | −$89.0M | $14.1M | −$88.3M | −$110.1M | −$103.9M |
| Capital expenditure | $9.82M | $45.0M | $30.6M | $13.7M | $154.0K | $848.0K |
| Free cash flow | −$51.1M | −$134.0M | −$16.6M | −$102.1M | −$110.3M | −$104.7M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25†Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $791.0K | — | $109.2M | $0 | $0 | — | — | — |
| Growth (year over year) | +434.5% | — | +12667.7% | −100.0% | −100.0% | — | — | — |
| Operating income | −$34.8M | — | $74.2M | −$34.7M | −$36.1M | — | −$23.7M | −$36.5M |
| Operating margin | −4398.1% | — | 67.9% | — | — | — | — | — |
| Net income | −$31.2M | — | $76.6M | −$32.5M | −$34.4M | — | −$21.6M | −$34.5M |
| Net margin | −3947.7% | — | 70.1% | — | — | — | — | — |
| EPS (diluted) | −$0.37 | — | $0.89 | −$0.38 | −$0.40 | — | −$0.11 | −$0.17 |
| Balance sheet | ||||||||
| Cash and equivalents | $52.6M | $58.4M | $51.9M | $56.9M | $55.5M | $61.9M | $51.0M | $49.6M |
| Total assets | $388.6M | $353.2M | $315.6M | $284.7M | $244.7M | $223.7M | $326.6M | $287.0M |
| Total liabilities | $192.9M | $191.9M | $75.2M | $74.8M | $68.4M | $64.8M | $61.8M | $54.7M |
| Shareholders' equity | $195.7M | $161.4M | $240.4M | $209.9M | $176.3M | $158.9M | $264.7M | $232.3M |
| Cash flow | ||||||||
| Operating cash flow | −$28.3M | — | −$34.6M | −$27.6M | −$25.6M | — | −$25.3M | −$19.8M |
| Capital expenditure | — | — | $475.0K | $317.0K | $195.0K | — | $584.0K | $694.0K |
| Free cash flow | — | — | −$35.1M | −$27.9M | −$25.8M | — | −$25.8M | −$20.5M |
From Century Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Century Therapeutics in our feed yet.